Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine

J Infect Chemother. 2022 Feb;28(2):304-307. doi: 10.1016/j.jiac.2021.10.018. Epub 2021 Oct 25.

Abstract

A 67-year-old Japanese man was admitted to our hospital with severe coronavirus disease 2019 (COVID-19) in March 2020. Mechanical ventilation was initiated 8 days after admission, due to severe respiratory failure. Multiple severe complications such as liver dysfunction, arrhythmia, brain infarction, and venous thromboembolism were also observed. We initially diagnosed Coombs test-positive warm autoimmune hemolytic anemia. Corticosteroids proved ineffective and anemia worsened with severe erythroid hypoplasia (0.5% erythroblasts in bone marrow), so we diagnosed pure red cell aplasia (PRCA). We also identified massive infiltration of cytotoxic T-lymphocytes expressing CD8, granzyme B, and perforin in bone marrow. Systemic cyclosporine was started, with full resolution of anemia and no need for blood transfusions after 4 weeks. We believe that this represents the first report of COVID-19-associated PRCA successfully treated using cyclosporine.

Keywords: COVID-19; Cyclosporine; Pure red cell aplasia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anemia, Hemolytic, Autoimmune* / drug therapy
  • COVID-19*
  • Cyclosporine / therapeutic use
  • Humans
  • Male
  • Red-Cell Aplasia, Pure* / drug therapy
  • SARS-CoV-2

Substances

  • Cyclosporine